The inhibitory effect of deferoxamine on DNA synthesis in human lymphocytes.
As an iron-chelating agent, deferoxamine (DFO) is widely used in treating iron poisoning and disorders of iron overload. This study demonstrates that DFO is a potent S-phase inhibitor of DNA synthesis in human lymphocytes in vitro, and this inhibitory effect of DFO is reversible by adding appropriate amounts of ferric ion. As a nontoxic and selective-S-phase inhibitor, it may play a role in immunosuppression in experimental and therapeutic situations. It may even become an auxiliary therapy for leukemia or other malignant tumors.
Wang
S T
ST
Jin
K L
KL
Li
T H
TH
D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis* / Q000187:drug effects; D003676:Deferoxamine / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000378:metabolism*
D004247:DNA; D003676:Deferoxamine